Compare Novo Nordisk A/S (NVO) vs Transocean Ltd (RIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Transocean Ltd — how do they compare? Novo Nordisk A/S trades at $38.2 (market cap $168.73B), while Transocean Ltd trades at $5.56 (market cap $6.19B). The key difference: Novo Nordisk A/S is far larger — about 27.3× Transocean Ltd's market cap, and Novo Nordisk A/S pays a 4.7% dividend while Transocean Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Transocean Ltd for 18 Days on average.
| NVO | RIG | |
|---|---|---|
Market Cap | $168.73B | $6.19B |
Volume | 13,531,267 | 30,564,415 |
Sector | Health | Energy |
52-Week High | $63.98 | $7.58 |
52-Week Low | $35.29 | $3.08 |
Typical Hold Time | 116 Days | 18 Days |
Enterprise Value | $183.05B | $10.80B |
Dividend Yield | 4.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, up 1.73% with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat estimates, with Q2 2026 EPS of $0.96 surpassing the $0.82 expectation. The company maintains robust cash flow generation of $119.1B from operations in 2025.
NVO presents compelling value with a 9.71 P/E ratio and 16.8% upside to the $44.67 consensus target. Key risks include FDA regulatory delays for hemophilia drug denecimig and intensifying competition from Eli Lilly in obesity treatments. The bullish analyst consensus (59% buy ratings) supports the growth outlook despite near-term headwinds.
RIG trades at $5.39, down 0.19% on the day, with a mixed technical picture showing bearish moving averages but neutral oscillators. The company reported a net loss of $2.92 billion in 2025, though revenue remains solid at $3.97 billion. Recent news highlights progress on the $5.8 billion Valaris acquisition and new contract wins, while analyst sentiment is divided with a 39% buy rating.
The outlook hinges on successful deleveraging and offshore cycle strength, but high debt and persistent losses pose significant risks. Investment appeal is speculative, dependent on cash flow improvements and debt reduction outweighing current profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →
